S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Modern Day Options Trading For Beginners! (Ad)pixel
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
Modern Day Options Trading For Beginners! (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Modern Day Options Trading For Beginners! (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Modern Day Options Trading For Beginners! (Ad)pixel
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
Modern Day Options Trading For Beginners! (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Modern Day Options Trading For Beginners! (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Modern Day Options Trading For Beginners! (Ad)pixel
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
Modern Day Options Trading For Beginners! (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Modern Day Options Trading For Beginners! (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Modern Day Options Trading For Beginners! (Ad)pixel
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
Modern Day Options Trading For Beginners! (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Modern Day Options Trading For Beginners! (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
NASDAQ:CRSP

CRISPR Therapeutics - CRSP Stock Forecast, Price & News

$43.43
+0.29 (+0.67%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$42.00
$43.86
50-Day Range
$43.14
$56.12
52-Week Range
$38.94
$86.95
Volume
890,032 shs
Average Volume
992,671 shs
Market Capitalization
$3.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$72.89

CRISPR Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
67.8% Upside
$72.89 Price Target
Short Interest
Bearish
14.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of CRISPR Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$3.52 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($7.54) to ($5.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

506th out of 1,005 stocks

Biological Products, Except Diagnostic Industry

90th out of 168 stocks


CRSP stock logo

About CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRSP Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Intellia's (NTLA) HAE Therapy Granted RMAT by the FDA
CRISPR Therapeutics AG (NASDAQ:CRSP) Short Interest Update
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
Ready to Buy the Dip? Consider This Gene Editing Stock
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
Prime Medicine 'Crispr 3.0' Vs. Crispr Therapeutics
See More Headlines
Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRSP Company Calendar

Last Earnings
2/21/2023
Today
3/25/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRSP
Fax
N/A
Employees
473
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$72.89
High Stock Price Forecast
$123.00
Low Stock Price Forecast
$39.00
Forecasted Upside/Downside
+67.8%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
18 Analysts

Profitability

Net Income
$-650,170,000.00
Net Margins
-54,271.70%
Pretax Margin
-54,298.84%

Debt

Sales & Book Value

Annual Sales
$1.20 million
Book Value
$23.95 per share

Miscellaneous

Free Float
74,479,000
Market Cap
$3.42 billion
Optionable
Optionable
Beta
1.73

Key Executives

  • Dr. Rodger Novak M.D. (Age 55)
    Founder, Chairman & Pres
  • Dr. Samarth  KulkarniDr. Samarth Kulkarni (Age 43)
    CEO & Director
    Comp: $1.18M
  • Dr. Lawrence Otto Klein Ph.D. (Age 40)
    Chief Operating Officer
    Comp: $675k
  • Mr. James R. KasingerMr. James R. Kasinger (Age 50)
    Gen. Counsel & Sec.
    Comp: $648.93k
  • Mr. Shaun Foy
    Founder
  • Dr. Emmanuelle Marie Charpentier
    Co-Founder & Scientific Advisory Board Member
  • Dr. Craig C. Mello Ph.D.
    Scientific Founder & Advisory Board Member
  • Dr. Chad Cowan Ph.D.
    Scientific Founder
  • Dr. Matthew Porteus M.D. (Age 56)
    Ph.D., Scientific Founder & Advisory Board Member
  • Dr. Daniel G. Anderson Ph.D.
    Scientific Founder & Advisory Board Member













CRSP Stock - Frequently Asked Questions

Should I buy or sell CRISPR Therapeutics stock right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There are currently 1 sell rating, 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CRSP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRSP, but not buy additional shares or sell existing shares.
View CRSP analyst ratings
or view top-rated stocks.

What is CRISPR Therapeutics' stock price forecast for 2023?

18 equities research analysts have issued 1 year price targets for CRISPR Therapeutics' stock. Their CRSP share price forecasts range from $39.00 to $123.00. On average, they predict the company's share price to reach $72.89 in the next twelve months. This suggests a possible upside of 67.8% from the stock's current price.
View analysts price targets for CRSP
or view top-rated stocks among Wall Street analysts.

How have CRSP shares performed in 2023?

CRISPR Therapeutics' stock was trading at $40.65 at the start of the year. Since then, CRSP shares have increased by 6.8% and is now trading at $43.43.
View the best growth stocks for 2023 here
.

When is CRISPR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our CRSP earnings forecast
.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) issued its earnings results on Tuesday, February, 21st. The company reported ($1.41) earnings per share for the quarter, topping the consensus estimate of ($2.27) by $0.86. The firm earned $6 million during the quarter, compared to analysts' expectations of $7.37 million. CRISPR Therapeutics had a negative trailing twelve-month return on equity of 31.85% and a negative net margin of 54,271.70%. CRISPR Therapeutics's quarterly revenue was down 53.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.84) EPS.

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (10.00%), Sumitomo Mitsui Trust Holdings Inc. (5.12%), Nikko Asset Management Americas Inc. (5.12%), T. Rowe Price Investment Management Inc. (3.82%), NEA Management Company LLC (2.03%) and Price T Rowe Associates Inc. MD (1.43%). Insiders that own company stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, Tony W Ho and Tony W Ho.
View institutional ownership trends
.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $43.43.

How much money does CRISPR Therapeutics make?

CRISPR Therapeutics (NASDAQ:CRSP) has a market capitalization of $3.42 billion and generates $1.20 million in revenue each year. The company earns $-650,170,000.00 in net income (profit) each year or ($8.37) on an earnings per share basis.

How many employees does CRISPR Therapeutics have?

The company employs 473 workers across the globe.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The official website for the company is www.crisprtx.com. The company can be reached via phone at (141) 561-3277 or via email at susan.kim@crisprtx.com.

This page (NASDAQ:CRSP) was last updated on 3/25/2023 by MarketBeat.com Staff